Related Experiment Video
Updated: Apr 4, 2026

Th17 Inflammation Model of Oropharyngeal Candidiasis in Immunodeficient Mice
Published on: February 18, 2015
A 15-year-old boy with severe combined immunodeficiency, fungal infection, and weight gain
Mehtap Haktanir Abul1, Karen Tuano, C Mary Healy
1Section of Immunology, Allergy and Rheumatology, Department of Pediatrics, Baylor College of Medicine, Texas Children's Hospital, Houston, Texas, USA.
Insights
Hematopoietic stem cell transplantation (HSCT) is most effective for X-linked severe combined immune deficiency in infants under 3 months without other health issues. Suboptimal outcomes can still occur, leading to infections and complications from antifungal treatments.
Area of Science:
- Immunology
- Hematology
- Pediatric Medicine
Background:
- X-linked severe combined immune deficiency (X-linked SCID) requires timely intervention for optimal outcomes.
- Hematopoietic stem cell transplantation (HSCT) is a primary treatment for X-linked SCID.
- Early diagnosis and treatment are critical for improving patient survival and quality of life.
Observation:
- HSCT outcomes in X-linked SCID are best in patients under 3 months old, without comorbidities, and with matched sibling donors.
- Incomplete cellular engraftment can lead to persistent immune dysfunction, affecting B and natural killer cell function.
- Protein-losing enteropathies and low immunoglobulin levels (IgA, IgG, IgM) can occur with immune deficiencies.
Findings:
- Even with optimal conditions, HSCT may not achieve full engraftment, resulting in suboptimal immune reconstitution.
- Patients with immune deficiencies are susceptible to specific infections predicted by their immune dysfunction.
- Fungal infections, though rare in immunocompromised hosts, require careful evaluation and management due to potential drug-drug interactions with antifungals.
Implications:
- Early HSCT in X-linked SCID is crucial, but strategies are needed to address suboptimal engraftment and immune function.
- Understanding infection risks associated with specific immune deficiencies can guide proactive monitoring and treatment.
- Managing coexisting fungal infections in immunocompromised patients necessitates careful consideration of antifungal therapy and potential drug interactions.
Abstract:
Hematopoietic stem cell transplantation (HSCT) outcomes in X-linked severe combined immune deficiency are most effective when performed with patients <3 months of age and without coexisting morbidity, and with donor cells from a matched sibling. Even under such favorable circumstances, outcomes can be suboptimal, and full cellular engraftment may not be complete, which results in poor B or natural killer cell function. Protein losing enteropathies can accompany persistent immune deficiency disorders with resultant low serum globulins (immunoglobulin A [IgA], IgG, IgM) and lymphopenia. Patients with immune disorders acquire infections that can be predicted by their immune dysfunction. Fungal infections are typically noted in neutropenic (congenital or acquired) and T-cell deficient individuals. Coexisting fungal infections are rare, even in hosts who are immunocompromised, and they require careful evaluation. Antifungal treatment may result in drug-drug interactions with significant complications.
Related Concept Videos
Immunodeficiency Diseases
There are three main causes of immunodeficiency...
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Cytomegalovirus Disease
Fungal Phylum Microsporidia
Cystic Fibrosis: Management
Sinus disease and chronic...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

